Drugs / Troxerutin
Troxerutin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06355258 | Dec 2023 → Dec 2024 overdue | — | Westlake University | Recruiting | No outcome recorded |
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT01848210 | May 2013 → Sep 2015 | chronic venous insufficiency | Takeda | Completed | Missed primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Troxerutin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06355258 ↗ |
| Known as | 3',4',7-tris(hydroxyethyl)rutin | ChEMBL registry synonym — accepted as the source's own label CHEMBL3182320 ↗ |
| Known as | NSC-758937 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3182320 ↗ |
| Known as | Troxerutina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3182320 ↗ |
| Known as | Troxerutine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3182320 ↗ |
| Known as | Z 6000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3182320 ↗ |
| Modality | Small molecule | — CHEMBL3182320 ↗ |
| Route | Oral | “Coumarin 30 mg, troxerutin 180 mg fixed-dose combination tablets, orally, three times daily for up to 16 weeks.” NCT01848210 ↗ |